-
Mashup Score: 8Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer - 19 hour(s) ago
Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer - 13 day(s) ago
Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer #gyncsm #oncology #medtwitter https://t.co/JAzcORWoFo
-
-
Mashup Score: 6
Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens @myESMO @AngelesSecord #gyncsm #oncology #MedTwitter https://t.co/ZFMNJOD32D
-
-
Mashup Score: 6
Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens @myESMO @AngelesSecord #gyncsm #oncology #MedTwitter https://t.co/ZFMNJOD32D
-
-
Mashup Score: 6
Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens @myESMO @AngelesSecord #gyncsm #oncology #MedTwitter https://t.co/ZFMNJOD32D
-
-
Mashup Score: 2
Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer @uamshealth @uamscancer @JAMAOnc #gyncsm #oncology #medtwitter https://t.co/YDg10jrfQ6
-
-
Mashup Score: 2
Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer @uamshealth @uamscancer @JAMAOnc #gyncsm #oncology #medtwitter https://t.co/YDg10jrfQ6
-
-
Mashup Score: 0
Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer @uamshealth @uamscancer @JAMAOnc #gyncsm #oncology #medtwitter https://t.co/YDg10jrfQ6
-
-
Mashup Score: 2
Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Preclinical Study Reveals Potential Role for GLP-Agonists in Endometrial Cancer @DKrauseMD @StephensonCC #gyncsm #oncology #MedTwitter https://t.co/jntJT0bBWA
-
-
Mashup Score: 1
Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Preclinical Study Reveals Potential Role for GLP-Agonists in Endometrial Cancer @DKrauseMD @StephensonCC #gyncsm #oncology #MedTwitter https://t.co/jntJT0bBWA
-
Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer #gyncsm #oncology #medtwitter https://t.co/JAzcORWoFo